Moderna stock crumbled Thursday after the biotech company missed sales estimates for its two products, Spikevax and mResvia.

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The ...

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Pharmaceutical company Moderna ( NASDAQ: MRNA) is set to report its first quarter earnings results on Thursday, May 1st, ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

The HHS will invest $176 million in a mRNA vaccine from Moderna meant to protect against an avian influenza pandemic.